Research Analysts Set Expectations for Rezolute Q1 Earnings

Rezolute, Inc. (NASDAQ:RZLT) – Stock analysts at HC Wainwright decreased their Q1 2027 earnings per share (EPS) estimates for shares of Rezolute in a report released on Monday, March 30th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of ($0.18) per share for the quarter, down from their previous estimate of ($0.08). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Rezolute’s Q2 2027 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.09) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.57) EPS.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings results on Thursday, February 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.06).

RZLT has been the subject of a number of other reports. Cantor Fitzgerald cut shares of Rezolute from an “overweight” rating to a “neutral” rating in a research note on Thursday, December 11th. Craig Hallum downgraded shares of Rezolute from a “buy” rating to a “hold” rating and set a $2.00 price objective for the company. in a research note on Thursday, December 11th. Maxim Group set a $4.00 target price on Rezolute in a research report on Friday, December 12th. Wall Street Zen cut Rezolute from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $20.00 price target on shares of Rezolute in a report on Friday, December 5th. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Rezolute currently has an average rating of “Hold” and a consensus target price of $8.00.

Rezolute Trading Up 2.6%

Shares of RZLT opened at $3.13 on Wednesday. The company’s fifty day simple moving average is $3.15 and its 200-day simple moving average is $5.67. The company has a market cap of $299.54 million, a P/E ratio of -3.37 and a beta of 0.65. Rezolute has a twelve month low of $1.07 and a twelve month high of $11.46.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets purchased a new stake in Rezolute in the 2nd quarter valued at about $25,000. Russell Investments Group Ltd. purchased a new position in shares of Rezolute during the third quarter worth approximately $61,000. Ameritas Investment Partners Inc. purchased a new position in shares of Rezolute during the second quarter worth approximately $30,000. Legal & General Group Plc bought a new stake in shares of Rezolute during the second quarter valued at approximately $32,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Rezolute during the third quarter valued at approximately $94,000. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.